eprintid: 10162570
rev_number: 7
eprint_status: archive
userid: 699
dir: disk0/10/16/25/70
datestamp: 2023-01-05 10:18:26
lastmod: 2023-01-05 10:18:26
status_changed: 2023-01-05 10:18:26
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Batzu, Lucia
creators_name: Rota, Silvia
creators_name: Hye, Abdul
creators_name: Heslegrave, Amanda
creators_name: Trivedi, Dhaval
creators_name: Gibson, Lucy L
creators_name: Farrell, Chloe
creators_name: Zinzalias, Pavlos
creators_name: Rizos, Alexandra
creators_name: Zetterberg, Henrik
creators_name: Chaudhuri, K Ray
creators_name: Aarsland, Dag
title: Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease
ispublished: pub
divisions: UCL
divisions: B02
divisions: C07
divisions: D07
divisions: F86
keywords: Science & Technology, Life Sciences & Biomedicine, Neurosciences, Neurosciences & Neurology, NONMOTOR SYMPTOMS SCALE, ALZHEIMERS-DISEASE, TAU, BIOMARKER, IMPAIRMENT, PREDICTION, DIAGNOSIS, ACCURACY, DEMENTIA, DECLINE
note: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
abstract: Early identification of cognitive impairment in Parkinson’s disease (PD) has important clinical and research implications. The aim of our study was to investigate the role of plasma tau phosphorylated at amino acid 181 (p-tau181) and plasma neurofilament light chain (NfL) as biomarkers of cognition in PD. Baseline concentrations of plasma p-tau181 and NfL were measured in a cohort of 136 patients with PD and 63 healthy controls (HC). Forty-seven PD patients were followed up for up to 2 years. Cross-sectional and longitudinal associations between baseline plasma biomarkers and cognitive progression were investigated using linear regression and linear mixed effects models. At baseline, plasma p-tau181 concentration was significantly higher in PD subjects compared with HC (p = 0.026). In PD patients, higher plasma NfL was associated with lower MMSE score at baseline, after adjusting for age, sex and education (p = 0.027). Baseline plasma NfL also predicted MMSE decline over time in the PD group (p = 0.020). No significant association between plasma p-tau181 concentration and baseline or longitudinal cognitive performance was found. While the role of p-tau181 as a diagnostic biomarker for PD and its relationship with cognition need further elucidation, plasma NfL may serve as a feasible, non-invasive biomarker of cognitive progression in PD.
date: 2022-11-12
date_type: published
publisher: NATURE PORTFOLIO
official_url: https://doi.org/10.1038/s41531-022-00384-x
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1984934
doi: 10.1038/s41531-022-00384-x
medium: Electronic
pii: 10.1038/s41531-022-00384-x
lyricists_name: Zetterberg, Henrik
lyricists_name: Heslegrave, Amanda
lyricists_id: HZETT94
lyricists_id: AJHES09
actors_name: Bracey, Alan
actors_id: ABBRA90
actors_role: owner
funding_acknowledgements: [National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust]; [King's College London]; [Wolfson Foundation]; [Royal Society]; 2018-02532 [Swedish Research Council]; 681712 [European Research Council]; ALFGBG-720931 [Swedish State Support for Clinical Research]; 201809-2016862 [Alzheimer Drug Discovery Foundation (ADDF), USA]; ADSF-21-831376-C [AD Strategic Fund]; ADSF-21-831381-C [AD Strategic Fund]; ADSF-21-831377-C [AD Strategic Fund]; ADSF-21-831376-C [Alzheimer's Association]; ADSF-21-831381-C [Alzheimer's Association]; ADSF-21-831377-C [Alzheimer's Association]; [Olav Thon Foundation]; [Erling-Persson Family Foundation]; [Stiftelsen for Gamla Tjanarinnor]; FO2019-0228 [Hjarnfonden, Sweden]; 860197 [European Union's Horizon 2020 research and innovation program under the Marie Skodowska-Curie grant]; JPND2021-00694 [European Union Joint Program for Neurodegenerative Disorders]; [UK Dementia Research Institute at UCL]
full_text_status: public
publication: npj Parkinson's Disease
volume: 8
article_number: 154
pages: 7
event_location: United States
issn: 2373-8057
citation:        Batzu, Lucia;    Rota, Silvia;    Hye, Abdul;    Heslegrave, Amanda;    Trivedi, Dhaval;    Gibson, Lucy L;    Farrell, Chloe;                     ... Aarsland, Dag; + view all <#>        Batzu, Lucia;  Rota, Silvia;  Hye, Abdul;  Heslegrave, Amanda;  Trivedi, Dhaval;  Gibson, Lucy L;  Farrell, Chloe;  Zinzalias, Pavlos;  Rizos, Alexandra;  Zetterberg, Henrik;  Chaudhuri, K Ray;  Aarsland, Dag;   - view fewer <#>    (2022)    Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease.                   npj Parkinson's Disease , 8     , Article 154.  10.1038/s41531-022-00384-x <https://doi.org/10.1038/s41531-022-00384-x>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10162570/1/s41531-022-00384-x.pdf